LFG
MCRB icon

Larson Financial Group’s Seres Therapeutics MCRB Stock Holding History

Larson Financial Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12
Closed -$195 – 3158
2024
Q4 		$195 Hold
12
– – ﹤0.01% 2449
2024
Q3 		$222 Hold
12
– – ﹤0.01% 2338
2024
Q2 		$170 Hold
12
– – ﹤0.01% 2116
2024
Q1 		$182 Hold
12
– – ﹤0.01% 1648
2023
Q4 		$329 Hold
12
– – ﹤0.01% 1615
2023
Q3 		$559 Hold
12
– – ﹤0.01% 1566
2023
Q2 		$1.13K Hold
12
– – ﹤0.01% 1348
2023
Q1 		$1.33K Hold
12
– – ﹤0.01% 1309
2022
Q4 		$1.32K Hold
12
– – ﹤0.01% 1255
2022
Q3 		$2K Buy
+12
New +$1.23K ﹤0.01% 1125

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Larson Financial Group's MCRB Position: Q1 2025 in Review

Larson Financial Group sold out of Seres Therapeutics (MCRB) in Q1 2025, closing a stake of 12 shares — an estimated $195 sold.

Larson Financial Group first reported a position in MCRB in Q3 2022 and held it in 10 quarters. The position peaked at $2K in Q3 2022. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

  • Larson Financial Group reported no remaining Seres Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Larson Financial Group sold 12 Seres Therapeutics shares in Q1 2025, an estimated $195.
  • Larson Financial Group first reported a position in Seres Therapeutics in Q3 2022 and held it in 10 quarters.
  • Larson Financial Group's Seres Therapeutics position peaked at $2K in Q3 2022.
  • 63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on Larson Financial Group's 13F filing for Q1 2025, filed 2 May 2025.